Compare GSK plc (GSK) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TotalEnergies SE — how do they compare? GSK plc trades at $52.65 (market cap $101.34B), while TotalEnergies SE trades at $78.98 (market cap $178.73B). The key difference: TotalEnergies SE is the larger of the two by market cap, and TotalEnergies SE pays the higher dividend (5.25%). Which is the better fit depends on your goals.
| GSK | TTE | |
|---|---|---|
Market Cap | $101.34B | $178.73B |
Sector | Health | Energy |
52-Week High | $61.18 | $93.60 |
52-Week Low | $36.20 | $57.39 |
Enterprise Value | $121.95B | $212.87B |
Dividend Yield | 3.49% | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
TotalEnergies (TTE) trades at $79.23, down 2.08% on the day, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 11.92 and P/S of 0.96, supported by strong cash flow generation of $27.3B in 2025. Recent news highlights strategic moves including LNG shipments to Asia and divestments to focus on profitable renewables. Earnings beat expectations in Q1 2026 with EPS of $2.45 versus $2.22 estimated.
Outlook remains positive given low valuation, shareholder returns via dividends, and operational resilience amid geopolitical events. Risks include exposure to oil price volatility and regulatory pressures on emissions. Analyst consensus is strongly bullish with 19 buys out of 33 ratings, indicating confidence in continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
